World Library  
Flag as Inappropriate
Email this Article

Relugolix

Article Id: WHEBN0048188195
Reproduction Date:

Title: Relugolix  
Author: World Heritage Encyclopedia
Language: English
Subject: Elagolix, Cetrorelix acetate, Ganirelix, Goserelin, Gonadotropin
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Relugolix

Relugolix
Systematic (IUPAC) name
1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
Clinical data
Routes of
administration
Oral
Identifiers
CAS Registry Number
ATC code H01
PubChem CID:
ChemSpider
Synonyms TAK-385
Chemical data
Formula C29H27F2N7O5S
Molecular mass 623.630386 g/mol

Relugolix (INN) (developmental code name TAK-385) is a non-peptide, orally-active, selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (IC50 = 0.12 nM)[1] that is under development for clinical use by Takeda.[2][3] It is currently in phase II clinical trials for the treatment of endometriosis, uterine leiomyoma, and prostate cancer.[3][4][5][1]

A single oral administration of relugolix at a dose of 3 mg/kg has been found to suppress luteinizing hormone levels for more than 24 hours in castrated cynomolgus monkeys, indicating a long duration of action.[2] The drug (80–160 mg/day) has been found to reduce testosterone levels to sustained castrate levels in men with once-daily chronic administration.[1] Lower dosages (10–40 mg/day) are being studied in the treatment of endometriosis and uterine leiomyoma to achieve partial sex hormone suppression.[4] The reasoning behind partial suppression for these conditions is to reduce the incidence and severity of menopausal symptoms such as hot flushes and to avoid bone mineral density changes caused by estrogen deficiency that can eventually lead to osteoporosis.[4][6]

See also

References

  1. ^ a b c http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2013.CN.1.SAT-318
  2. ^ a b Miwa, Kazuhiro; Hitaka, Takenori; Imada, Takashi; Sasaki, Satoshi; Yoshimatsu, Mie; Kusaka, Masami; Tanaka, Akira; Nakata, Daisuke; Furuya, Shuichi; Endo, Satoshi; Hamamura, Kazumasa; Kitazaki, Tomoyuki (2011). "Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor". Journal of Medicinal Chemistry 54 (14): 4998–5012.  
  3. ^ a b Nakata, Daisuke; Masaki, Tsuneo; Tanaka, Akira; Yoshimatsu, Mie; Akinaga, Yumiko; Asada, Mari; Sasada, Reiko; Takeyama, Michiyasu; Miwa, Kazuhiro; Watanabe, Tatsuya; Kusaka, Masami (2014). "Suppression of the hypothalamic–pituitary–gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: Studies in human GnRH receptor knock-in mice". European Journal of Pharmacology 723: 167–174.  
  4. ^ a b c Streuli, Isabelle; de Ziegler, Dominique; Borghese, Bruno; Santulli, Pietro; Batteux, Frédéric; Chapron, Charles (2012). "New treatment strategies and emerging drugs in endometriosis". Expert Opinion on Emerging Drugs 17 (1): 83–104.  
  5. ^ Elancheran, R.; Maruthanila, V. L.; Ramanathan, M.; Kabilan, S.; Devi, R.; Kunnumakara, A.; Kotoky, Jibon (2015). "Recent discoveries and developments of androgen receptor based therapy for prostate cancer". Med. Chem. Commun. 6 (5): 746–768.  
  6. ^ Struthers, R. Scott; Nicholls, Andrew J.; Grundy, John; Chen, Takung; Jimenez, Roland; Yen, Samuel S. C.; Bozigian, Haig P. (2009). "Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix". The Journal of Clinical Endocrinology & Metabolism 94 (2): 545–551.  

External links

  • Relugolix - AdisInsight



This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.